Gufic BioSciences Ltd

As of December 3, 2025, Gufic BioScience is overvalued with a PE ratio of 61.64 and a Price to Book Value of 5.56, significantly higher than its peers, indicating that its current price of 349.85 is not justified given its low ROE of 9.02% and recent stock performance.

As of 24-Nov, Gufic BioSciences Ltd has witnessed a modest price increase, rising by 0.41% to ₹354.65, continuing a five-day rally that has delivered a 12.66% gain over the past week. This upward movement contrasts with the company’s recent financial challenges and broader market underperformance, prompting a closer examination of the factors driving the stock’s current trajectory.

As of 19-Nov, Gufic BioSciences Ltd is currently priced at 335.05, reflecting a recent increase and strong intraday trading activity, despite a longer-term decline of 26.05% year-to-date. The stock's recent performance indicates a positive shift in investor sentiment, outperforming the Sensex over the past week.

Gufic BioSciences reported strong Q2 FY26 net sales of ₹237.05 crores, up 16.10% year-on-year, but faced significant profitability challenges with a net profit decline of 22.74% and a reduced PAT margin of 7.10%, primarily due to rising interest and employee costs. Overall, while revenue growth is positive, the profitability issues raise concerns.

Gufic BioScience's historical performance for the fiscal year ending March 2025 shows increased net sales and improved cash flow, but decreased profitability with lower operating profit, profit before tax, and earnings per share compared to March 2024. Total assets and liabilities rose, indicating a stable financial position despite challenges in margins.

Gufic BioScience's historical performance from March 2024 to March 2025 shows mixed results, with net sales increasing to 819.81 Cr but a decline in profit after tax to 69.65 Cr and a decrease in profit margins. However, cash flow from operating activities improved significantly to 122.00 Cr, indicating a positive cash flow trend.

As of 10-Nov, Gufic BioSciences Ltd's stock price is Rs 317.20, down 5.26%, reflecting a trend reversal after two days of gains and significant selling pressure. The company has faced declining profits over the last three quarters, contributing to a year-to-date decline of 29.99% and underperformance compared to the broader market.

As of October 29, 2025, Gufic BioScience is considered overvalued with a high PE ratio of 54.86 and a PEG ratio of 0.00, indicating no expected growth, and its stock has underperformed the Sensex by 26.18% year-to-date.

As of October 28, 2025, Gufic BioScience is considered very expensive and overvalued, with a PE ratio of 55.45 and an EV to EBITDA of 27.92, significantly higher than peers like Sun Pharma and Cipla, while also experiencing a year-to-date decline of 25.38% compared to the Sensex's gain of 8.30%.

Gufic BioScience's historical performance from March 2024 to March 2025 shows increased net sales and operating income, but declines in operating profit, profit before tax, and profit after tax. Despite improved cash flow, overall profitability metrics have decreased.

As of October 27, 2025, Gufic BioScience is considered overvalued with a PE ratio of 54.99 and an EV to EBITDA ratio of 27.70, despite a slight improvement in valuation grade, as its performance metrics like ROE and ROCE do not justify these high ratios and its PEG ratio indicates no expected earnings growth.

As of 24-Oct, Gufic BioSciences Ltd's stock price is Rs 342.00, down 0.86%, and has declined for eight consecutive days, totaling a 6.62% drop. The company faces negative investor sentiment due to poor quarterly results and underperformance compared to the Sensex, which has gained 7.77% year-to-date.